Interpretable deep learning survival predictive tool for small cell lung cancer

Author:

Zhang Dongrui,Lu Baohua,Liang Bowen,Li Bo,Wang Ziyu,Gu Meng,Jia Wei,Pan Yuanming

Abstract

BackgroundSmall cell lung cancer (SCLC) is an aggressive and almost universally lethal neoplasm. There is no accurate predictive method for its prognosis. Artificial intelligence deep learning may bring new hope.MethodsBy searching the Surveillance, Epidemiology, and End Results database (SEER), 21,093 patients’ clinical data were eventually included. Data were then divided into two groups (train dataset/test dataset). The train dataset (diagnosed in 2010–2014, N = 17,296) was utilized to conduct a deep learning survival model, validated by itself and the test dataset (diagnosed in 2015, N = 3,797) in parallel. According to clinical experience, age, sex, tumor site, T, N, M stage (7th American Joint Committee on Cancer TNM stage), tumor size, surgery, chemotherapy, radiotherapy, and history of malignancy were chosen as predictive clinical features. The C-index was the main indicator to evaluate model performance.ResultsThe predictive model had a 0.7181 C-index (95% confidence intervals, CIs, 0.7174–0.7187) in the train dataset and a 0.7208 C-index (95% CIs, 0.7202–0.7215) in the test dataset. These indicated that it had a reliable predictive value on OS for SCLC, so it was then packaged as a Windows software which is free for doctors, researchers, and patients to use.ConclusionThe interpretable deep learning survival predictive tool for small cell lung cancer developed by this study had a reliable predictive value on their overall survival. More biomarkers may help improve the prognostic predictive performance of small cell lung cancer.

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference66 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. Canadian Cancer statistics 2019;Committee;Toronto ON: Can Cancer Soc,2019

3. Current diagnosis and management of small-cell lung cancer;Wang;Mayo Clin Proc,2019

4. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials;Travis;J Clin Oncol,2013

5. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3